• KOL
    • Rheumatoid Arthritis
    • Karel Pavelka
    • Karel Pavelka: Influence Statistics

      Karel Pavelka

      Karel Pavelka

      Show email address

      Institute of Rheumatology, Prague, Czechia | Department of Rheumatology, 1, st, Faculty of Medicine, Charles University, Prague, Czechia | Institute of Rheumatology, Na Slupi ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Karel Pavelka:Expert Impact

      Concepts for whichKarel Pavelkahas direct influence:Rheumatoid arthritis,Knee osteoarthritis,Ankylosing spondylitis,Czech republic,Patients rheumatoid arthritis,Psoriatic arthritis,Serum levels.

      Karel Pavelka:KOL impact

      Concepts related to the work of other authors for whichfor which Karel Pavelka has influence:Rheumatoid arthritis,Ankylosing spondylitis,Necrosis factor,Rheumatic diseases,Radiographic progression,Knee pain,Monoclonal antibodies.

      KOL Resume for Karel Pavelka

      Year
      2022

      Institute of Rheumatology, Prague, Czechia

      2021

      Institute of Rheumatology, Na Slupi 4, 128 00 Prague 2, Czech Republic

      1st Faculty of Medicine, Charles University in Prague

      2020

      Institute of Rheumatology and Clinic of Rheumatology, Prague, Czech Republic

      2019

      Institute of Rheumatology, Prague and Clinic of Rheumatology, Charles University, Prague, Czech Republic

      2018

      Institute of Rheumatology, Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic

      2017

      Institute of Rheumatology, Charles University, Prague, Czech Republic

      2016

      Institute of Rheumatology, Prague, and Faculty of Medicine 1, Charles University Prague, Na Slupi 4, Prague, CZ 12850 Czech Republic

      2015

      ATTRA , Czech Republic.

      Institute of Rheumatology and Clinic of Rheumatology, Charles University Prague, Prague, Czech Republic

      2014

      Institute of Rheumatology & Clinic of Rheumatology, Charles University, Prague, Czech Republic

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Karel Pavelka is among the top experts in the world.
      Concept World rank
      hsp90 levels association #1
      arginine arthroplasty #1
      genetic biomarker diagnosis #1
      elisa comp #1
      womac osteoarthritis pain #1
      dm patients s100a11 #1
      mapping quality life #1
      synovitis joint tenderness #1
      development hyperuricemia glut9 #1
      08 synvisc #1
      brodalumab treatment subjects #1
      study baseline − #1
      single assay validation #1
      s100a11 netosis markers #1
      il40 autoantibodies #1
      daily chondroitin #1
      cee patients #1
      wpaira improvements #1
      disability czech attra #1
      backgroundcalgizzarin #1
      drugs alclofenac #1
      asdascrp serum il6 #1
      urine pentosidine auscan #1
      erosive disease pain #1
      s100a11 plasma #1
      healthy controls hsp90 #1
      illness spondylarthritis tenascin #1
      hc s100a11 #1
      15 abcg2 exons #1
      etanercept–methotrexate therapy #1
      s100a11 myositis #1
      wall males #1
      comp sera #1
      asu schedule drug #1
      arm 5 infliximab #1
      visfatin months #1
      rs750972998 #1
      serum arginine arthroplasty #1
      abp das28crp #1
      combo patients #1
      − week #1
      hc hsp90 levels #1
      vomiting treatment initiation #1
      response etn50 methotrexate #1
      esr lda #1
      261 psa #1
      variance antibodies illness #1
      lower concentrations clu #1
      haq us7s #1
      attra ankylosing #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Karel Pavelka

      KOL-Index: 22236

      OBJECTIVE: To compare the efficacy and safety of adalimumab plus methotrexate (MTX) versus MTX monotherapy or adalimumab monotherapy in patients with early, aggressive rheumatoid arthritis (RA) who had not previously received MTX treatment.

      METHODS: This was a 2-year, multicenter, double-blind, active comparator-controlled study of 799 RA patients with active disease of < 3 years' duration who had never been treated with MTX. Treatments included adalimumab 40 mg subcutaneously every ...

      Known for Combination Therapy | Adalimumab Mtx | Clinical Trial | Methotrexate Treatment | Premier Study
      KOL-Index: 21356

      BACKGROUND: Clinical remission and low disease activity are essential treatment targets in patients with rheumatoid arthritis. Although moderately active rheumatoid arthritis is common, treatment effects in moderate disease have not been well studied. Additionally, optimum use of biologics needs further investigation, including the use of induction, maintenance, and withdrawal treatment strategies. The aim of the PRESERVE trial was to assess whether low disease activity would be ...

      Known for Methotrexate Patients | Low Disease Activity | Rheumatoid Arthritis | Randomised Controlled Trial | Treatment Etanercept
      KOL-Index: 21052

      BACKGROUND: Biological agents offer good control of rheumatoid arthritis, but the long-term benefits of achieving low disease activity with a biological agent plus methotrexate or methotrexate alone are unclear. The OPTIMA trial assessed different treatment adjustment strategies in patients with early rheumatoid arthritis attaining (or not) stable low disease activity with adalimumab plus methotrexate or methotrexate monotherapy.

      METHODS: This trial was done at 161 sites worldwide. ...

      Known for Methotrexate Patients | Low Disease | Rheumatoid Arthritis | Primary Endpoint | Activity Adalimumab
      KOL-Index: 19835

      BACKGROUND: Etanercept and methotrexate are effective in the treatment of rheumatoid arthritis but no data exist on concurrent initiation or use of the combination compared with either drug alone. We aimed to assess combination treatment with etanercept and methotrexate versus the monotherapies in patients with rheumatoid arthritis.

      METHODS: In a double-blind, randomised, clinical efficacy, safety, and radiographic study, 686 patients with active rheumatoid arthritis were randomly ...

      Known for Rheumatoid Arthritis | Etanercept Methotrexate | Combination Treatment | 24 Weeks | Total Sharp Score
      KOL-Index: 18907

      BACKGROUND: Roughly a third of patients with rheumatoid arthritis treated with biological treatments receive them as monotherapy. Tocilizumab--an inhibitor of interleukin 6 receptor signalling--has been studied as monotherapy in several clinical trials. We assessed the efficacy and safety of tocilizumab monotherapy compared with adalimumab monotherapy for patients with rheumatoid arthritis.

      METHODS: We did this randomised, double-blind, parallel-group, phase 4 superiority study in 76 ...

      Known for Adalimumab Monotherapy | Rheumatoid Arthritis | Patients Tocilizumab | Baseline Das28 | Phase 4
      KOL-Index: 17302

      OBJECTIVE: To evaluate the efficacy and safety of 2 dosage regimens of lyophilized certolizumab pegol (a novel PEGylated anti-tumor necrosis factor agent) as adjunctive therapy to methotrexate (MTX) in patients with active rheumatoid arthritis (RA) with an inadequate response to MTX therapy alone.

      METHODS: In this 52-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial, 982 patients were randomized 2:2:1 to receive treatment with subcutaneous ...

      Known for Certolizumab Pegol | Active Rheumatoid Arthritis | Placebo Mtx | Physical Function | Phase Iii
      KOL-Index: 15908

      OBJECTIVE: To estimate the annual incidence and prevalence of psoriatic arthritis (PsA), ankylosing spondylitis (AS), and reactive arthritis (ReA) in a sample of the Czech population.

      METHODS: The population-based study was conducted in two regions of the Czech Republic (with a total population of 186000 inhabitants) in 2002-2003. Incident cases were registered on condition of confirming a definite diagnosis according to existing classification criteria during the study period (1 March ...

      Known for Psoriatic Arthritis | Czech Republic | Ankylosing Spondylitis | Incidence Prevalence | Total Population
      KOL-Index: 15877

      OBJECTIVES: ABP 501 is a Food and Drug Administration-approved biosimilar to adalimumab; structural, functional and pharmacokinetic evaluations have shown that the two are highly similar. We report results from a phase III study comparing efficacy, safety and immunogenicity between ABP 501 and adalimumab.

      METHODS: In this randomised, double-blind, active comparator-controlled, 26-week equivalence study, patients with moderate to severe active rheumatoid arthritis (RA) despite ...

      Known for Abp 501 | Adalimumab Patients | Safety Immunogenicity | Rheumatoid Arthritis | Phase Iii
      KOL-Index: 15601

      BACKGROUND: Resistin is a newly identified adipocytokine which has demonstrated links between obesity and insulin resistance in rodents. In humans, proinflammatory properties of resistin are superior to its insulin resistance-inducing effects.

      OBJECTIVES: To assess resistin expression in synovial tissues, serum and synovial fluid from patients with rheumatoid arthritis, osteoarthritis and spondylarthropathies (SpA), and to study its relationship with inflammatory status and rheumatoid ...

      Known for Rheumatoid Arthritis | Synovial Fluid | Serum Resistin | Inflammation Disease Activity
      KOL-Index: 15572

      OBJECTIVE: To develop evidence based recommendations for the management of hip osteoarthritis (OA).

      METHODS: The multidisciplinary guideline development group comprised 18 rheumatologists, 4 orthopaedic surgeons, and 1 epidemiologist, representing 14 European countries. Each participant contributed up to 10 propositions describing key clinical aspects of hip OA management. Ten final recommendations were agreed using a Delphi consensus approach. Medline, Embase, CINAHL, Cochrane Library, ...

      Known for Hip Osteoarthritis | Eular Evidence | Based Recommendations | Task Force | Strength Recommendation
      KOL-Index: 14975

      OBJECTIVE: To establish the safety and efficacy of repeat infusions of tocilizumab (previously known as MRA), a humanized anti-interleukin-6 (IL-6) receptor antibody, alone and in combination with methotrexate (MTX), for the treatment of rheumatoid arthritis (RA).

      METHODS: The study group comprised 359 patients with active RA in whom the response to MTX was inadequate. During a stabilization period, these patients received their current dose of MTX for at least 4 weeks. Following ...

      Known for Tocilizumab Mtx | Patients 8 | Monoclonal Antibodies | Monotherapy Combination | Rheumatoid Arthritis
      KOL-Index: 14879

      OBJECTIVE: To compare the efficacy and safety of etanercept and sulfasalazine, alone and in combination, in patients with active rheumatoid arthritis despite sulfasalazine treatment.

      METHODS: A double-blind, randomised study in adult patients with active rheumatoid arthritis despite stable sulfasalazine (2-3 g/day) treatment. The primary end point was a 20% response by the American College of Rheumatology (ACR) criteria at 24 weeks.

      RESULTS: At baseline, the three treatment groups ...

      Known for Etanercept Sulfasalazine | Rheumatoid Arthritis | 24 Weeks | Baseline Week | Necrosis Factor
      KOL-Index: 14653

      BackgroundSecukinumab, an anti–interleukin-17A monoclonal antibody, improved the signs and symptoms of ankylosing spondylitis (AS) in two phase 3 studies (MEASURE 1 and MEASURE 2). Here, we present 52-week results from the MEASURE 3 study assessing the efficacy and safety of secukinumab 300 and 150 mg subcutaneous maintenance dosing, following an intravenous loading regimen.MethodsA total of 226 patients were randomized to intravenous secukinumab 10 mg/kg (baseline, weeks 2 and 4) ...

      Known for 3 Study | Ankylosing Spondylitis | Monoclonal Antibodies | Secukinumab Placebo | Efficacy Safety
      KOL-Index: 14209

      OBJECTIVE: To compare the effectiveness of tocilizumab (TCZ) and tumour necrosis factor (TNF) inhibitors (TNFi) as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) after the use of at least one biologic DMARD (bDMARD).

      METHODS: We included patients with RA having used at least one bDMARD from 10 European registries. We compared drug retention using Kaplan-Meier and Cox models and Clinical ...

      Known for Tnf Inhibitors | Rheumatoid Arthritis | Modifying Antirheumatic | Tcz Monotherapy | Synthetic Disease
      KOL-Index: 14112

      OBJECTIVE: To assess the pain and functional disability levels corresponding to an indication for total joint replacement (TJR) in hip and knee osteoarthritis (OA).

      METHODS:

      DESIGN: International cross-sectional study in 10 countries.

      PATIENTS: Consecutive outpatients with definite hip or knee OA attending an orthopaedic outpatient clinic. Gold standard measure for recommendation for TJR: Surgeon's decision that TJR is justified.

      OUTCOME MEASURES: Pain (ICOAP: intermittent and constant ...

      Known for Total Joint Replacement | Knee Osteoarthritis | Patients Tjr | International Cross | Hip Arthroplasty

      Key People For Rheumatoid Arthritis

      Top KOLs in the world
      #1
      Paul Emery
      rheumatoid arthritis ankylosing spondylitis radiographic progression
      #2
      Josef Sebastian Smolen
      rheumatoid arthritis systemic lupus erythematosus radiographic progression
      #3
      James F Fries
      rheumatoid arthritis physical function systemic lupus erythematosus
      #4
      John Turner Sharp
      rheumatoid arthritis radiographic progression joint space width
      #5
      Frederick J Wolfe
      rheumatoid arthritis work disability rheumatic diseases
      #6
      Matthew H Liang
      rheumatoid arthritis systemic lupus erythematosus lyme disease

      Institute of Rheumatology, Prague, Czechia | Department of Rheumatology, 1, st, Faculty of Medicine, Charles University, Prague, Czechia | Institute of Rheumatology, Na Slupi 4, 128 00 Prague 2, Czech Republic | Department of Experimental Rheumatolog

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.